Baxter International Inc. - BAX STOCK NEWS

Baxter International (NYSE:BAX) hosted its 2022 Investor Conference, outlining its strategy for growth and innovation following the Dec. 2021 acquisition of Hillrom. The company aims to enhance patient care and operational efficiency, expecting constant currency sales growth of 4-5% from 2022-2025, with a projected adjusted operating margin increase of 350-400 basis points by 2025. Baxter anticipates $350 million in annual cost synergies and $200 million in revenue synergies by 2025 from the acquisition. Innovations showcased include the Sharesource platform and Voalte communication technologies.

Baxter International Inc. (NYSE:BAX) will host an investor conference on May 25, 2022, in Glenview, Ill.. The conference aims to provide insights into the company's growth strategy, innovation pipeline, and financial outlook. Starting at 8:00 a.m. CT, attendees can explore the innovation hall featuring product advancements, followed by management presentations at 8:30 a.m. CT. The event will also be available via live webcast on Baxter’s corporate website. Registered participants will be able to access the details of the event.

Baxter International (NYSE:BAX) has increased its quarterly cash dividend by approximately 3.5% to $0.29 per share, up from $0.28. The dividend is payable on July 1, 2022, to stockholders of record as of June 3, 2022, resulting in an annual dividend rate of $1.16 per share. CEO José Almeida emphasized the company's commitment to delivering shareholder value and advancing innovation, marking the seventh consecutive year of dividend growth.

Baxter International reported strong first-quarter 2022 results with revenues of $3.7 billion, a 26% increase year-over-year. U.S. GAAP earnings per share (EPS) were $0.14, while adjusted EPS rose 22% to $0.93. The company anticipates full-year sales growth of 23%-24% and adjusted EPS of $4.12-$4.20. Notably, acquisitions contributed significantly, with around $755 million from Hillrom. However, the Novum IQ infusion system faces FDA review delays, affecting outlook. An Investor Conference is scheduled for May 25, 2022.

Baxter International Inc. (NYSE:BAX) announced findings from a study on the Starling Registry presented at the Society of Critical Care Medicine Congress. The study, involving 127 critical care patients, indicates that monitoring stroke volume and cardiac output can predict mortality rates. Patients showing improved stroke volume had a mortality rate of 14.9%, compared to 35.0% for those without improvement. Baxter emphasizes the importance of non-invasive monitoring technology for personalized treatment decisions. The company plans further assessments of hemodynamic monitoring across various clinical settings.

Baxter International (NYSE:BAX) has received FDA 510(k) clearance for its ST Set, enhancing continuous renal replacement therapy (CRRT) options. Previously authorized under Emergency Use Authorization due to COVID-19, the ST Set includes three sizes and utilizes Baxter's proprietary AN69 membrane for effective blood purification. This approval is expected to meet the increased demand for CRRT amid rising acute kidney injury cases, thereby expanding patient access to critical care solutions. The ST Set is already in use across multiple regions, including Europe and Asia Pacific.

Baxter International Inc. (NYSE:BAX) will host a conference call on April 28, 2022, at 7:30 a.m. Central Time to discuss its first-quarter financial results. Participants can pre-register for the call via the provided link. The call will also be webcasted on Baxter's website. Baxter is a leading global medtech company providing critical care, kidney care, and other medical products used widely across healthcare settings.

Baxter International Inc. (NYSE:BAX), a leader in medtech, will present at the Barclays Global Healthcare Conference on Thursday, March 17, 2022, at 8:00 a.m. ET. Jay Saccaro, Baxter's CFO, will be presenting. Investors can access the live webcast on Baxter's website, with a replay available until September 13, 2022. The company has a portfolio of products serving patients worldwide, highlighting its commitment to innovative healthcare solutions for nearly 90 years.

Baxter International (NYSE:BAX) has released new data indicating that its Sharesource remote patient management platform may enhance clinical effectiveness for home dialysis patients. A study presented at the World Congress of Nephrology showed that patients using Sharesource experienced an average increase of 3.4 months in time on therapy compared to those without the platform. This research involved nearly 1,500 patients in Colombia over a two-year period, supporting the growing evidence that digital health solutions are beneficial in kidney care.